Wealth Enhancement Trust Services
AMPH icon

Wealth Enhancement Trust Services’s Amphastar Pharmaceuticals AMPH Stock Holding History

Wealth Enhancement Trust Services’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-35
Closed -$706 – 817
2026
Q2 		$706 Buy
+35
New +$706 ﹤0.01% 1190

Other funds holding AMPH

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Denali Advisors
Denali Advisors San Diego, California $996M AUM 25.54% 1-Year Est. Return
Bridge City Capital
Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return

Wealth Enhancement Trust Services's AMPH Position: Q3 2026 in Review

Wealth Enhancement Trust Services sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2026, closing a stake of 35 shares — an estimated $706 sold.

Wealth Enhancement Trust Services first reported a position in AMPH in Q2 2026 and held it in 1 quarter. The position peaked at $706 in Q2 2026. 160 funds tracked by Wall St. Rank hold AMPH as of Q3 2026.

  • Wealth Enhancement Trust Services reported no remaining Amphastar Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Trust Services sold 35 Amphastar Pharmaceuticals shares in Q3 2026, an estimated $706.
  • Wealth Enhancement Trust Services first reported a position in Amphastar Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Trust Services's Amphastar Pharmaceuticals position peaked at $706 in Q2 2026.
  • 160 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q3 2026, filed 7 Oct 2026.